BGT-002

Overview

BGT-002 (326E) is an orally active dual ACLY inhibitor and PPARα agonist. BGT-002 reduces lipogenesis by inhibiting synthesis and promoting efflux. BGT-002 demonstrates efficacy in ameliorating metabolic dysfunction-associated steatohepatitis (MASH) and improving hyperlipidemia in vivo. BGT-002 can be used for hypercholesterolemia and MASH research.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Hypercholesterolemia | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > ATP Citrate Lyase | Products > Signaling Pathways > PPAR

Product Information

• Catalog No.: HY-179591
• CAS No.: 2127387-94-2
• Molecular Formula: C19H34O4
• Molecular Weight: 326.47
• Purity: 99.35%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 2.5 mg/mL (7.66 mM); Clear solution
• Availability: In-stock

Source

Original product source